Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 691

1.

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

Blood Cells Mol Dis. 2000 Oct;26(5):453-66.

PMID:
11112383
2.

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.

Medicine (Baltimore). 1996 Nov;75(6):300-26.

3.

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Acta Haematol. 1995;94(3):128-34.

PMID:
7502628
4.

Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.

Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW.

N Engl J Med. 1993 Jan 14;328(2):73-80.

5.

Hydroxyurea therapy in thalassemia.

Loukopoulos D, Voskaridou E, Stamoulakatou A, Papassotiriou Y, Kalotychou V, Loutradi A, Cozma G, Tsiarta H, Pavlides N.

Ann N Y Acad Sci. 1998 Jun 30;850:120-8.

PMID:
9668534
6.

Hydroxyurea therapy in children severely affected with sickle cell disease.

Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.

J Pediatr. 1996 Jun;128(6):820-8.

PMID:
8648542
7.

Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.

Koren A, Segal-Kupershmit D, Zalman L, Levin C, Abu Hana M, Palmor H, Luder A, Attias D.

Pediatr Hematol Oncol. 1999 May-Jun;16(3):221-32.

PMID:
10326220
8.

Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.

Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R.

Blood Cells Mol Dis. 2009 Jan-Feb;42(1):25-31. doi: 10.1016/j.bcmd.2008.08.003. Epub 2008 Oct 26.

PMID:
18954999
9.

Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia.

Jayabose S, Tugal O, Sandoval C, Patel P, Puder D, Lin T, Visintainer P.

J Pediatr. 1996 Oct;129(4):559-65.

PMID:
8859263
10.

Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle-cell/beta-thalassaemia.

Voskaridou E, Kalotychou V, Loukopoulos D.

Br J Haematol. 1995 Mar;89(3):479-84.

PMID:
7537527
11.
12.

Overview of pathophysiology and rationale for treatment of sickle cell anemia.

Rodgers GP.

Semin Hematol. 1997 Jul;34(3 Suppl 3):2-7. Review.

PMID:
9317195
13.

Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.

Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW.

N Engl J Med. 1990 Apr 12;322(15):1037-45.

14.

Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.

Charache S.

Semin Hematol. 1997 Jul;34(3 Suppl 3):15-21. Review.

PMID:
9317197
15.

Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.

Ware RE, Eggleston B, Redding-Lallinger R, Wang WC, Smith-Whitley K, Daeschner C, Gee B, Styles LA, Helms RW, Kinney TR, Ohene-Frempong K.

Blood. 2002 Jan 1;99(1):10-4.

16.

The role of hydroxyurea in sickle cell disease.

Halsey C, Roberts IA.

Br J Haematol. 2003 Jan;120(2):177-86. Review. No abstract available. Erratum in: Br J Haematol. 2003 Apr;121(1):200.

PMID:
12542474
17.
18.

Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease.

Maier-Redelsperger M, de Montalembert M, Flahault A, Neonato MG, Ducrocq R, Masson MP, Girot R, Elion J.

Blood. 1998 Jun 15;91(12):4472-9.

19.

Hydroxyurea therapy in sickle cell anemia patients in CuraƧao, The Netherlands Antilles.

Saleh AW Jr, Velvis HJ, Gu LH, Hillen HF, Huisman TH.

Acta Haematol. 1997;98(3):125-9.

PMID:
9352741
20.

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.

Blood. 2004 Mar 15;103(6):2039-45. Epub 2003 Nov 20.

Supplemental Content

Support Center